Company news

Cardiol Therapeutics Inc. news in 2021

Cardiol Therapeutics Inc.'s news releases, calls and decks from 2021, newest first.

View company

Cardiol Therapeutics Announces Closing of US$50 Million Public Offering

November 5, 2021

Cardiol Therapeutics Announces Pricing of Public Offering of Units

November 3, 2021

Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Units

November 2, 2021

Cardiol Therapeutics Receives Health Canada Approval for Phase II Clinical Trial of CardiolRx(TM) for Acute Myocarditis

October 25, 2021

Cardiol Therapeutics Expands LANCER, a Phase II/III Trial of CardiolRx(TM), into Brazil, Mexico, and Canada

October 18, 2021

Cardiol Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference

September 16, 2021

Cardiol Therapeutics Announces Acceleration of Expiry Date of Warrants Issued on June 4, 2020

September 10, 2021

Cardiol Therapeutics Appoints Michael J. Willner to Its Board of Directors

September 7, 2021

Cardiol Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for Phase II Clinical Trial of CardiolRx(TM) for Acute Myocarditis

August 24, 2021

Cardiol Therapeutics to Commence Trading on NASDAQ Under the Symbol "CRDL"

August 9, 2021

Cardiol Therapeutics' Board of Directors Appoints Dr. Guillermo Torre-Amione as Chairman

July 7, 2021

Cardiol Therapeutics Reports Results of 2021 Annual General and Special Meeting

June 30, 2021

Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting on June 29th at 4: 30 p.m. EDT

June 28, 2021

Cardiol Therapeutics Closes $22 Million Bought Deal Offering

May 12, 2021

Cardiol Therapeutics Announces First Patient Enrolled in LANCER, a Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with COVID-19

April 28, 2021

Cardiol Therapeutics Announces Topline Results from Phase I Single and Multiple Ascending Dose Clinical Trial of CardiolRx(TM)

April 12, 2021

Cardiol Therapeutics Announces Filing of 2020 Year-End Financial Statements and MD&A

April 1, 2021

Cardiol Therapeutics Appoints Dr. Andrew Hamer as New Chief Medical Officer

March 30, 2021

Cardiol Therapeutics Submits Application for Uplisting to the Nasdaq and Raises Proceeds of Over $10 Million from Exercise of Warrants and Options

March 2, 2021

TMX Group, Cardiol Therapeutics, C-Suite at The Open

February 4, 2021

Cardiol Therapeutics Announces Formation of Data Safety Monitoring and Clinical Endpoint Committees for Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with COVID-19

January 21, 2021

Cardiol Therapeutics to Participate in Upcoming Virtual Investor Conferences

January 7, 2021

Decks in 2021